{"name":"Minerva Neurosciences","slug":"minerva","ticker":"NERV","exchange":"NASDAQ","domain":"minervaneurosciences.com","description":"Minerva Neurosciences is a biopharmaceutical company focused on the development of therapies for the treatment of central nervous system (CNS) disorders, including schizophrenia, bipolar disorder, and anxiety disorders. The company's lead product, roluperidone, has shown promise in treating schizophrenia. Minerva Neurosciences is a relatively small company with a limited product portfolio, but it has a strong pipeline of potential treatments.","hq":"Waltham, MA","founded":0,"employees":"","ceo":"Remy Luthringer, PhD","sector":"CNS / Psychiatry","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":41175600,"revenueGrowth":0,"grossMargin":0,"rdSpend":5759473,"netIncome":-293423177,"cash":97968888,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Roluperidone patent cliff ($100M at risk)","drug":"Roluperidone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MIN-117 5.0 mg","genericName":"MIN-117 5.0 mg","slug":"min-117-5-0-mg","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"MIN-117 5.0 mg","genericName":"MIN-117 5.0 mg","slug":"min-117-5-0-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Minerva Neurosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"The company reported a net loss of $13.4 million for the fourth quarter and $54.7 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"regulatory","headline":"Minerva Neurosciences Announces FDA Acceptance of New Drug Application for Roluperidone","summary":"The FDA has accepted the NDA for roluperidone, a treatment for schizophrenia.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"deal","headline":"Minerva Neurosciences Enters into Licensing Agreement with H. Lundbeck A/S","summary":"The company has entered into a licensing agreement with Lundbeck for the development and commercialization of roluperidone in the US and Canada.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9iS2R5RS13cjV6NjNRWG10dXRzS2hvMmQwSDNGVVE4Ujd5MVc1eEhRdm00NHBmUzZWNWw1QlRVZDN1WU1ZbFF3T2RRRURNQWZQLWREZ09pVElYTUFOV3JhdzNLazNTYWRJUjZqZ2drc2R5VkFO?oc=5","date":"2026-04-02","type":"pipeline","source":"investingnews.com","summary":"Minerva Announces Leadership Transition - investingnews.com","headline":"Minerva Announces Leadership Transition","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5Cck5XQ3pGR2hsa2Y2Ql8wX0Q3SXJoSjIyTVBOOHFiR2RJLVhISUtld0hJU0ZUMlM2bjM2V0hfcTducGcwcFVWY29aaUxydFdhc1FKdldMSXF3bUF3WmJnVHpVX21kRHla?oc=5","date":"2026-04-01","type":"regulatory","source":"MarketBeat","summary":"Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV - MarketBeat","headline":"Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOTmxwcUlfdnJyV2ZFVVdldUZoOW1ZX2tqRGNYdFdYWVV0LXg4ekc1Q0QyOHhCRnFRNXNUNVBuUk1wSG1jbVI3aVdEXzZObHA0QmJOM2l6ZGpYQ3VxRFpsUEE3amI4TmZmTEs5cmh5N0IxYmFHcmMtOHZCRnBjUk9ORWxPdXk2M25vR182OHJNTmZkbDlGSk9EWkt1ejVaRV9GSldqV3l1YThhUUp0eE1kRlRMc3gtLTJYd0NQUkJMdUZjT1ZhYnVVQU1McHFrSEk0T3BjNTBVbm9RS3VpT0YtR3had04xb1VkeGxXeVU5WTIxQ0V3V0tNZVZnVDEzRjFjZXI4TDJsUlNNaXdNOE54S0NkRl9kM2N0MEE?oc=5","date":"2026-03-31","type":"trial","source":"investingnews.com","summary":"Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - investingnews.com","headline":"Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Trea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNWm1vVTVqNmV0X21RYUgyaDdKamQwVzlaWElFVDI5d1JFcW5FdTFyWmhSRGhaYXktYkN6cXRsdHEtWHVvZFZ5emtjV2pGbmY0QmpOSmcwaWhDdlAyei0zRU9nVktPMzliblh2U2pOOTZjMmFpdVZSU3Frb09JQjBhdjRvTzdXaV94N2xOLUlIdlA1TC1SQkJXRUxqdzNoVkd4bno1R0ZxSXdjVmtlcWg0bXVlakxfQlprSWt3bEJjQkU?oc=5","date":"2026-03-25","type":"trial","source":"Stock Titan","summary":"Schizophrenia drug combo showed no safety issues as Phase 3 starts - Stock Titan","headline":"Schizophrenia drug combo showed no safety issues as Phase 3 starts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNZVBvMUtMVEp0S0piNUxId0F4Qjl1TTctc3MwelExUXdPSkNqbTlmRWV2bVMwakJZWnVVVmhveDdFeFp4elY0S2ZmdXh2d2NYSlZBd3doQnJsR1lveXVwR3hnM3FmeFRKTVB4SjRkYjViYkZfdWlWSEU5OEpsQ2RqdDNaUlFNdlFxUWdhc0JIU0s2Z1BDQUwyRzZPb1hhZG44TXdvVEN1WHVJdFZIUXdRUFZJRWJlNHFqRnlVaGJLR3lEYVlsOTR2S0lCQWdERzBUaVVENFAxSUtqQjlIaEFQRjlTSmdISEpXUEZObUFwUnB5bjhuWnhJ?oc=5","date":"2026-03-25","type":"regulatory","source":"investingnews.com","summary":"Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - investingnews.com","headline":"Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanza","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5jeEI2TjJTbVNuY180TUQ5N2hGeGQ1Y1IwZjM5bmt4N01tOXJuN1BnMGc5Zm5mMk1BeXYycnQ5VVJ2dk5yZ3VhUlBpXzZKVVBTcVFVVWU4aTFBQUhYcW13dEg5OGU4VGk0NENMX2FR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Minerva Neurosci (NERV) - Stock Titan","headline":"If You Invested $1,000 in Minerva Neurosci (NERV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQa1hfX045b2FGbjVSV2NDZVB4OGwta2paaVdvdU5IemhiVmNhTml5V0R3ZEYzcGdpX2hxUC1nS0owZ2RVN3FlY3Znek5hbHdTeTJ6RHg3TS1kNmFnNFlIQU50WW8tVWs5bVVqR0twQVhBeXJxVnRRRndZNDkwam9ld0ktMmRnUUpCaVRqVWVRWklUREp2RndWZ1lTOV9aczg0eVE?oc=5","date":"2026-03-12","type":"pipeline","source":"investingnews.com","summary":"Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - investingnews.com","headline":"Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPY3pWYTZyVnJIYlcwdDkzLU1aUWFVWFVUamZzLTF0Y1l6a04xaW9mWFpkc1Jyc3ZBZFpFYXFqQ2h2VlFTNDV1RjNjUmRNcmR2MGRMT3VubGxRNWllVjNGRDlmNjVXcmpMbWtScjlFQmlMRTBscjBBdEVWenFJY0lwZjdBeWJnQThYMHMwcHJSQ1JrQzhT?oc=5","date":"2026-03-11","type":"earnings","source":"Yahoo Finance","summary":"Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates - Yahoo Finance","headline":"Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-16","type":"pipeline","source":"simplywall.st","summary":"Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st","headline":"Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who o","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1FekJUa2RSTjU4cXp4TmQ1OTIzRVZKRERHcnpLZGlINl83VkkzSzBmUWdudWtfRTZQOENROURnOHhsZTNTM1BLQ3pvTlVrcDM0T0t2OFF3eXdzMEhWNi1kclpuVjNlUVZuUWNlcVEyN0REX1kwX0x3TVhDN19Sdw?oc=5","date":"2025-10-21","type":"deal","source":"Rolling Out","summary":"Minerva Neurosciences stock skyrockets after $200M deal - Rolling Out","headline":"Minerva Neurosciences stock skyrockets after $200M deal","sentiment":"neutral"}],"patents":[{"drugName":"Roluperidone","drugSlug":"roluperidone","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":100000000}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alkermes","Intra-Cellular Therapies","Janssen Pharmaceuticals"],"therapeuticFocus":["Schizophrenia","Bipolar Disorder","Anxiety Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":41175600,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":41175600,"period":"2020-12-31"},{"value":41175600,"period":"2020-12-31"},{"value":0,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5759473,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-293423177,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":97968888,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}